Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Overcoming antigen escape following CD19-directed CAR-T therapy

Pablo Domizi • 24 Apr 2022
The 2022 Tandem Meetings
General CAR-T

Pablo Domizi, PhD, Stanford University, Stanford, CA, comments on strategies to overcome antigen escape following CD19-directed therapy. Strategies targeting multiple antigens such as CD19, CD20, and CD22 may become more relevant in the future and it is likely that the CAR-T therapy field switches from single to multi-targeted CAR-T therapy. In addition, approaches to recover CD19 expression after relapse following CAR-T therapy are also a promising avenue to tackle antigen escape. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Pablo Domizi

Mechanisms of antigen escape following CD19-directed CAR-T therapy
3:01
Mechanisms of antigen escape following CD19-directed CAR-T therapy
Pablo Domizi • 24 Apr 2022
Using single-cell multiomics to predict patients at risk for antigen escape after CAR-T therapy
1:55
Using single-cell multiomics to predict patients at risk for antigen escape after CAR-T therapy
Pablo Domizi • 24 Apr 2022

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals